



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

Pegylated Liposomal DOXOrubicin (Caelyx®)



* C L X - 0 0 0 0 0 - 0 4 - C N - M L *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Kaposi sarcoma.

Soft tissue sarcoma.

Late stages of ovarian cancer / uterine Cancer / cervical cancer.

Late stages of breast cancer.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC ≥ 1000; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min.

Pre-treatment Medications: (30-60 min before starting treatment)

Ondansetron 8 mg PO/IV

Dexamethasone 10 mg PO/IV

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
Caelyx	50 mg/m ²	IV in 250 mL D5W over 60 min. If total dose is < 90 mg, dilute in 250 mL D5W. If total dose is ≥ 90 mg, dilute in 500 mL D5W.	D1
To be repeated every 4 weeks until disease progression, intolerable toxicity, or reach the maximum tolerable dose of Caelyx.			

Special instructions: The maximum cumulative dose of Caelyx is 450 mg/m².

Treatment Description:

Cycle	Date	Caelyx	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No